In vitro regulation of B cell differentiation by interleukin-6 and soluble CD23 in systemic lupus erythematosus B cell subpopulations and antigen-induced normal B cells.

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Arthritis & Rheumatism

• Publication date

  1991-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/ART.1780340305PMID 1825912
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Recombinant soluble Fc epsilon receptor II (Fc epsilon RII/CD23) has IgE binding activity but no B cell growth promoting activity.

  1989cited by this paper
• Accessory cell activity of monocytes in anti-DNA antibody production in systemic lupus erythematosus.

  1989cited by this paper
• T cell receptor alpha/beta expressing double-negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis.

  1989cited by this paper
• Induction of neuronal differentiation in PC12 cells by B-cell stimulatory factor 2/interleukin 6

  1988cited by this paper
• Molecular and Functional Properties of Novel T Cell Subsets in C3H‐gld/gld and Nude Mice. Implications for Thymic and Extrathymic Maturation

  1988cited by this paper
• Correlation of T and B cell activities in vitro and serum IL-2 levels in systemic lupus erythematosus.

  1988cited by this paper
• B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes

  1988cited by this paper
• Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas

  1988cited by this paper
• Production of B cell-stimulating factors by B cells in patients with systemic lupus erythematosus.

  1988cited by this paper
• IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells.

  1988cited by this paper
• The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells

  1988cited by this paper
• Purification and partial biochemical characterization of IgE-binding factors secreted by a human B lymphoblastoid cell line.

  1987cited by this paper
• The activation antigen BLAST‐2, when shed, is an autocrine BCGF for normal and transformed B cells.

  1987cited by this paper
• Mechanisms of T and B cell collaboration in the in vitro production of anti-DNA antibodies in the NZB/NZW F1 murine SLE model.

  1987cited by this paper
• Human recombinant interleukin 4 induces Fc epsilon receptors (CD23) on normal human B lymphocytes

  1987cited by this paper
• Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells.

  1987cited by this paper
• The role of interferon-beta 1 and the 26-kDa protein (interferon-beta 2) as mediators of the antiviral effect of interleukin 1 and tumor necrosis factor.

  1987cited by this paper
• Evidence for an association between CD23 and the receptor for a low molecular weight B cell growth factor

  1986cited by this paper
• Human B lymphocytes capable of spontaneous Ig production in short-term cultures: characterization in the circulation and lymphoid tissues.

  1986cited by this paper
• Ligation of the CD23, p45 (BLAST‐2, EBVCS) antigen triggers the cell‐cycle progression of activated B lymphocytes

  1986cited by this paper
• Detection and characterization of monoclonal antibodies specific to IgE receptors on human lymphocytes by flow cytometry.

  1985cited by this paper
• Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2).

  1985cited by this paper
• Enzyme amplification can enhance both the speed and the sensitivity of immunoassays.

  1985cited by this paper
• The in vitro production of anti-DNA antibody by cultured peripheral blood or tonsillar lymphoid cells from normal donors and SLE patients.

  1985cited by this paper
• Defective monocyte production of, and T lymphocyte response to, interleukin-1 in the peripheral blood of patients with systemic lupus erythematosus.

  1984cited by this paper
• The in vitro production and regulation of anti-double stranded DNA antibodies by peripheral blood mononuclear cells from normals and patients with systemic lupus erythematosus.

  1984cited by this paper
• B Cell‐Tropic Interleukins in Murine Systemic Lupus Erythematosus (SLE) 1

  1984cited by this paper
• Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome.

  1983cited by this paper
• Immunological studies of homosexual men with immunodeficiency and Kaposi's sarcoma.

  1983cited by this paper
• Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE).

  1983cited by this paper
• The 1982 revised criteria for the classification of systemic lupus erythematosus.

  1982cited by this paper
• Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus.

  1982cited by this paper
• Subpopulations of circulating B cells and regulatory T cells involved in in vitro immunoglobulin E production in atopic patients with elevted serum immunoglobulin E.

  1980cited by this paper
• In vitro production of IgE by human peripheral blood mononuclear cells. I. Rate of IgE biosynthesis.

  1980cited by this paper
• Increased immunoglobulin-secreting cells in the blood of patients with active systemic lupus erythematosus.

  1980cited by this paper
• Inability of patients with common variable hypogammaglobulinemia to generate lymphjoblastoid B cells following booster immunization.

  1980cited by this paper
• Characterization of a circulating subpopulation of spontaneous antitetanus toxoid antibody producing B cells following in vivo booster immunization.

  1979cited by this paper
• Differential synthesis of IgM and IgA anti-tetanus toxoid antibody in vitro following in vivo booster immunization of humans.

  1979cited by this paper
• Immunoregulation in humans: control of antitetanus toxoid antibody production after booster immunization.

  1978cited by this paper
• Increased spontaneous activity of antibody-forming cells in the peripheral blood of patients with active SLE.

  1977cited by this paper
• Single step separation of human T and B cells using AET treated srbc rosettes.

  1976cited by this paper
• Immunoglobulin synthesis by peripheral blood cells in systemic lupus erythematosus.

  1975cited by this paper
• Separation of cells by velocity sedimentation

  1969cited by this paper
• Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

  1968cited by this paper
• Isolation and fractionation of nucleic acids.

  1964cited by this paper

• The Pathogenesis of Chronic Spontaneous Urticaria: The Role of Infiltrating Cells.

  2021cites this paper
• Systemic lupus erythematosus is associated with impaired autophagic degradation via interleukin-6 in macrophages.

  2020cites this paper
• The pathological role of B cells in systemic lupus erythematosus: From basic research to clinical

  2019cites this paper
• Correlation between Serum IL-6 Level and Th17/Treg Ratio with Systemic Lupus Erythematosus Disease Activity

  2019cites this paper
• Multiparametric flow cytometry analysis of peripheral blood B cell trafficking differences among Epstein-Barr virus infected and uninfected subpopulations.

  2019cites this paper
• IL‐6 and IL‐1β expression is increased in autologous serum skin test of patients with chronic spontaneous urticaria

  2019cites this paper
• Bet v 1‐specific IgE levels and PR‐10 reactivity discriminate silent sensitization from phenotypes of birch allergy

  2019cites this paper
• Efficiency of Tocilizumab Therapy for an Exacerbation of Systemic Lupus Erythematosus: A Review of Literature

  2018cites this paper
• Patient with Systemic Lupus Erythematosus Combined with Erosive Arthritis was Treated Successfully with Tocilizumab: A Case Report

  2018cites this paper
• Interleukin 6 Accelerates Mortality by Promoting the Progression of the Systemic Lupus Erythematosus-Like Disease of BXSB.Yaa Mice

  2016cites this paper
• Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis.

  2016cites this paper
• Structural basis of the broadly neutralizing anti‐interferon‐α antibody rontalizumab

  2015cites this paper
• The role of serum IL-17 and IL-6 as biomarkers of disease activity and predictors of remission in patients with lupus nephritis.

  2015cites this paper
• Cytokines and MicroRNAs as Candidate Biomarkers for Systemic Lupus Erythematosus

  2015cites this paper
• IL-17 is a key cytokine correlating with disease activity and clinical presentation of systemic lupus erythematosus

  2015cites this paper
• The role of cytokines in the pathogenesis of systemic lupus erythematosus – from bench to bedside

  2013cites this paper
• An ENU mutagenesis-derived mouse model with a dominant Jak1 mutation resembling phenotypes of systemic autoimmune disease.

  2013cites this paper
• Tocilizumab: An Updated Review of Its Use in the Treatment of Rheumatoid Arthritis and Its Application for Other Immune-Mediated Diseases

  2013cites this paper
• Immunotherapeutic implication of IL-6 blockade.

  2012cites this paper
• Successful use of interleukin 6 antagonist tocilizumab in a patient with refractory cutaneous lupus and urticarial vasculitis.

  2012cites this paper
• Serum progranulin levels are elevated in patients with systemic lupus erythematosus, reflecting disease activity

  2012cites this paper
• Tocilizumab for the Treatment of Rheumatoid Arthritis and Other Systemic Autoimmune Diseases: Current Perspectives and Future Directions

  2012cites this paper
• IL-6 promoter polymorphism (−174G/C) and systemic lupus erythematosus

  2012cites this paper
• Pathogenesis and future treatments of systemic lupus erythematosus : the role of cytokines and anti-cytokines? : peer reviewed review

  2011cites this paper
• In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment.

  2011cites this paper
• Tocilizumab, a humanized anti‐interleukin‐6 receptor antibody, for the treatment of autoimmune disorders

  2011cites this paper
• The Emerging Role of Monoclonal Antibodies in the Treatmentof Systemic Lupus Erythematosus

  2011cites this paper
• Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

  2010cites this paper
• Cytokines and Their Roles in the Pathogenesis of Systemic Lupus Erythematosus: From Basics to Recent Advances

  2010cites this paper
• A role for Fli-1 in B cell proliferation: implications for SLE pathogenesis.

  2008cites this paper
• Actividad del lupus eritematoso sistémico y marcadores sanguíneos asociados a aterosclerosis

  2008cites this paper
• Correlation between some Th1 and Th2 cytokine receptor gene polymorphisms and systemic lupus erythematosus in Chinese patients

  2007cites this paper
• Peripheral expression of RAG in human B lymphocytes in normal and pathological conditions is dependent on interleukin-6.

  2007cites this paper
• Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia

  2005cites this paper
• The role of cytokines in the immunopathogenesis of lupus

  2004cites this paper
• Rationale for interleukin-6 blockade in systemic lupus erythematosus

  2004cites this paper
• The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications

  2004cites this paper
• Biomarkers in systemic lupus erythematosus

  2004cites this paper
• Biomarkers in systemic lupus erythematosus: II. Markers of disease activity.

  2004cites this paper
• 44 – PATHOPHYSIOLOGY OF DRUG-INDUCED LUPUS

  2004cites this paper
• Cytokines and the regulation of heat shock proteins in Systemic Lupus Erythematosus.

  2003cites this paper
• IL-6 in autoimmune disease and chronic inflammatory proliferative disease.

  2002cites this paper
• Cytokine regulation of heat shock protein 90 gene expression with reference to systemic lupus erythematosus

  2001cites this paper
• Interleukin-6 promoter polymorphism (--174 G/C) in Caucasian German patients with systemic lupus erythematosus.

  2001cites this paper
• Impaired DNA Methylation in Lupus T Cells

  1999cites this paper
• Interleukin 6 and its Receptor: TenYears Later

  1998cites this paper
• Interleukin 6 and its receptor: ten years later.

  1998cites this paper
• The regulation of heat shock proteins and their role in systemic lupus erythematosus.

  1998cites this paper
• Subsets of activated T cells in patients with systemic lupus erythematosus: the relation to cell cycle.

  1997cites this paper
• Interleukin 6 activates heat-shock protein 90 beta gene expression.

  1997cites this paper
• The expression of lymphocyte function associated antigen-1, intercellular adhesion molecule-1 on peripheral blood lymphocytes in patients with systemic lupus erythematosus.

  1996cites this paper
• Involvement of interleukin-4 and soluble CD23 in hypersynthesis of immunoglobulins A and E in patients with IgA nephropathy.

  1996cites this paper
• Elevated levels of soluble Fc epsilon RII/CD23 and antibodies to Epstein-Barr virus in patients with Sjögren's syndrome.

  1996cites this paper
• Serum and urinary interleukin-6 in systemic lupus erythematosus

  1996cites this paper
• New concepts in the pathogenesis of drug-induced lupus.

  1995cites this paper
• Rapamycin inhibits the in vitro release of soluble CD23 by SAC/IL-2/IL-4-activated human peripheral blood B lymphocytes.

  1995cites this paper
• Interleukin‐6 expression in the skin of patients with lupus erythematosus

  1995cites this paper
• Anti-Interleukin-6 and Soluble Interleukin-6 Receptor in Systemic Lupus Erythematosus

  1994cites this paper
• Cytokine Gene Profile in Circulating Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus: Increased Interleukin-2 but not Interleukin-4 mRNA

  1994cites this paper
• Novel approaches to the preparation and use of monoclonal antibodies.

  1993cites this paper
• T- and B-cell abnormalities in systemic lupus.

  1993cites this paper
• Constitutive expression of IL-6 receptors and their role in the excessive B cell function in patients with systemic lupus erythematosus.

  1993cites this paper
• Up‐Regulation by Cyclosporine (CsA) of the In Vitro Release of Soluble CD23 (sCD23) and of the In Vitro Production of IL‐6 and IgM

  1993cites this paper
• Activation of IL‐6 production by UV irradiation of blood mononuclear cells from patients with systemic lupus erythematosus

  1992cites this paper
• Plasma concentration of IL‐6 in systemic lupus erythematosus; an indicator of disease activity?

  1992cites this paper
• Autostimulatory effects of IL‐6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL‐6 production and IL‐6R expression

  1992cites this paper